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Background
The theory and investigations on cancer stem cells
(CSCs) have received growing attention, as these cells
are responsible for the failure of cancer therapeutic stra-
tegies and the return of cancer.
Materials and methods
A complex tumorimmunological study on primary and
metastatic cancerous tissue biopsies and peripheral
blood of patients with malignant melanomas (n = 153)
has been performed with ethical permission (ETT
TUKEB 16462- 02/2010) and patients’ formal consent.
Results
We developed a methodology to select cancer initiating
cells from fresh cancer cell cultures of malignant melano-
mas. Characteristic cell growth pattern, spheroid forming,
CSC markers, like CD133, Nestin, ABCB5, CD20 and
unique GD3 ganglioside expression were defined by
immunofluorescence assay. Additionally tumor infiltrating
B cells’ sialilated glycosphingolipid binding was defined by
antibody phage display and immunglobulin repertoire ana-
lysis. Real Time PCR gene expression studies were done to
reveal molecular parameters of regulatory mechanisms.
Conclusion
We provide here a novel strategy to detect cancer initi-
ating cells in metastatic melanomas by double labeling
with anti CD20 antibodies and sialilated glycosphingoli-
pid antigen specific immunglobulins. With antibody
engineering present findings might be turned into a
novel cancer therapeutic approach targeting cancer stem
cells.
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